Identifying disease modifying genes in multiple sclerosis

被引:100
|
作者
Kantarci, OH
de Andrade, M
Weinshenker, BG
机构
[1] Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA
关键词
multiple sclerosis; genetics; prognosis; severity; course; outcome;
D O I
10.1016/S0165-5728(01)00481-7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Evidence is mounting that genetic variation influences not only susceptibility to multiple sclerosis (MS), but also its course and severity. Identification of disease modifying genes, however, poses unique challenges, especially on how to classify the course and outcome of the disease in ways that may be relevant to analysis of biological factors that might be influenced by genes, The power of the statistical approaches to detect small effects of individual genes in complex disorders such as MS is problematic, and approaches to estimate power must be appropriate for the data. Nonetheless, using contemporary schemes of classification, genetic variants that influence disease course have been found; in fact, a small number have been confirmed to influence disease course in two or more independent studies. This review addresses strategies relevant to identification of disease modifying genes in MS, and summarizes and critically evaluates the cur-rent state of knowledge in this area. (C) 2002 Elsevier Science B.V All rights reserved.
引用
收藏
页码:144 / 159
页数:16
相关论文
共 50 条
  • [21] Disease modifying treatments for multiple sclerosis - What is on the horizon?
    Weilbach, FX
    Gold, R
    CNS DRUGS, 1999, 11 (02) : 133 - 157
  • [22] Use of Disease-Modifying Drugs in Multiple Sclerosis
    Wurzius, F. Q.
    Silva, C. B.
    de Vecino, M. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 102 - 103
  • [23] Multiple Sclerosis, Disease-Modifying Therapies, and Infections
    Langer-Gould, Annette M.
    Smith, Jessica B.
    Gonzales, Edlin G.
    Piehl, Fredrik
    Li, Bonnie H.
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (06):
  • [24] Multiple sclerosis disease modifying medicine utilisation in Australia
    Hollingworth, Samantha
    Walker, Kimitra
    Page, Andrew
    Eadie, Mervyn
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (12) : 2083 - 2087
  • [25] Oral Disease-Modifying Therapies for Multiple Sclerosis
    Kim, Woojun
    Zandona, Manuella Edler
    Kim, Su-Hyun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2015, 11 (01): : 9 - 19
  • [26] Adherence to Disease-Modifying Therapies for Multiple Sclerosis
    Higuera, Lucas
    Carlin, Caroline S.
    Anderson, Sarah
    Journal of Managed Care & Specialty Pharmacy, 2016, 22 (12): : 1394 - 1401
  • [27] The effect of disease modifying therapies on fatigue in multiple sclerosis
    Rivera, Samantha Cruz
    Aiyegbusi, Olalekan Lee
    Meier, Daniela Piani
    Dunne, Achille
    Harlow, Danielle E.
    Henke, Christian
    Kamudoni, Paul
    Calvert, Melanie
    QUALITY OF LIFE RESEARCH, 2024, 33 : S194 - S194
  • [28] Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
    Erin E. Longbrake
    Becky J. Parks
    Anne H. Cross
    Current Neurology and Neuroscience Reports, 2013, 13
  • [30] New and emerging disease modifying therapies for multiple sclerosis
    Saidha, Shiv
    Eckstein, Christopher
    Calabresi, Peter A.
    YEAR IN IMMUNOLOGY, 2012, 1247 : 117 - 137